Hillgene's NK and TIL Cell Expansion Reagent (Feeder cell) is an irradiated and inactivated engineered K562 feeder cells expressing IL-21 and other cytokines, which, together with the mainstream immune cell culture medium, can activate and expand NK cells and tumor-infiltrating TIL cells derived from umbilical cord blood and peripheral blood mononuclear cells cultured in vitro, and the purity of the obtained NK and TIL cells is high.
Reliable NK,TIL expansion using K562 feeder system
NK and TIL expansion reagents with K562 feeder
K562 feeder reagents for efficient NK and TIL growth
D0: Plasma and PBMC isolation, inoculation and activation
D4: Observe and medium exchange
D6: Observe and medium infusion
D8: Observe and medium infusion, re-activation
D10: Observe and medium exchange
D12: Observe and medium infusion
D14: Harvest
| Performance Program | Indicator results |
| NK/CAR-NK cell expansion | Over 5000 times (14d) |
| NK/CAR-NK cell viability | > 90% |
| NK/CAR-NK Cell purity | > 95% |
Suitable for activation and mass expansion of different immune cells such as NK cells, CAR-NK cells and TIL.
Process Development Stage: Evaluate the in vitro expansion capacity of cells such as NK and TIL and optimize the process during the early development stage of cell therapy products.
Process locking, product production and comparability study phase: During the mid-term process locking, production and cell process change phase after IND approval for cell therapy products, establish stable cell expansion processes based on trophoblast cells, such as NK and TIL, and carry out process locking, cellular drug production and comparability studies for cell products.
Fold expansion and viability of different Donor-derived NK cells:
Purity of different Donor-derived NK cells:
86 198 5711 6962 
info@hillgene.com 
English
_20260106165102.webp "First-of-Its-Kind Fentanyl Vaccine Prepares to Enter Human Clinical Trials")
